Akero Therapeutics/$AKRO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Akero Therapeutics
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
Ticker
$AKRO
Sector
Primary listing
Employees
67
Headquarters
Website
AKRO Metrics
BasicAdvanced
$4.3B
-
-$3.78
-0.28
-
Price and volume
Market cap
$4.3B
Beta
-0.28
52-week high
$58.40
52-week low
$21.34
Average daily volume
2.4M
Financial strength
Current ratio
12.659
Quick ratio
12.29
Long term debt to equity
2.235
Total debt to equity
3.543
Interest coverage (TTM)
-67.37%
Profitability
EBITDA (TTM)
-321.458
Management effectiveness
Return on assets (TTM)
-20.36%
Return on equity (TTM)
-31.14%
Valuation
Price to book
4.21
Price to tangible book (TTM)
4.21
Price to free cash flow (TTM)
-16.03
Free cash flow yield (TTM)
-6.24%
Free cash flow per share (TTM)
-3.374
Growth
Earnings per share change (TTM)
11.00%
3-year earnings per share growth (CAGR)
6.30%
What the Analysts think about AKRO
Analyst ratings (Buy, Hold, Sell) for Akero Therapeutics stock.
Bulls say / Bears say
Publication of Phase 2b SYMMETRY results in the New England Journal of Medicine on May 9, 2025, showed 39% of patients on 50 mg EFX achieved ≥1-stage fibrosis improvement without worsening MASH (p=0.009), validating EFX’s potential as a best-in-class therapy (GlobeNewswire)
Cash, cash equivalents, and marketable securities of $1.128 billion as of March 31, 2025, with guidance to fund operations into 2028, providing ample runway for Phase 3 SYNCHRONY trials (GlobeNewswire)
Pricing of an upsized public offering of common stock for $350 million at $48.00 per share on January 28, 2025, underscores strong investor support and funds further clinical development of EFX (Nasdaq)
Novo Nordisk’s semaglutide (Wegovy) received accelerated FDA approval for MASH on August 15, 2025—the first GLP-1 therapy sanctioned for the indication—heightening competitive pressure on FGF21 analogs like EFX (Reuters)
Research and development expenses rose 37% year-over-year to $69.6 million in Q1 2025—driven by Phase 3 trial and manufacturing costs—potentially accelerating cash burn if not curtailed (GlobeNewswire)
European Association for the Study of Obesity guidelines now recommend GLP-1 agonists Wegovy and Zepbound as first-line obesity treatments—citing benefits for fatty liver disease among other comorbidities—which may shift treatment preference away from novel therapies like EFX (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2025.
AKRO Financial Performance
Revenues and expenses
AKRO Earnings Performance
Company profitability
AKRO News
AllArticlesVideos
Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc. - AKRO
Business Wire6 hours ago
Top Stock Movers Now: Delta Air Lines, PepsiCo, Akero Therapeutics, and More
Investopedia1 day ago
Novo Nordisk to acquire Akero Therapeutics for its experimental liver disease drug
Fast Company2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Akero Therapeutics stock?
Akero Therapeutics (AKRO) has a market cap of $4.3B as of October 11, 2025.
What is the P/E ratio for Akero Therapeutics stock?
The price to earnings (P/E) ratio for Akero Therapeutics (AKRO) stock is 0 as of October 11, 2025.
Does Akero Therapeutics stock pay dividends?
No, Akero Therapeutics (AKRO) stock does not pay dividends to its shareholders as of October 11, 2025.
When is the next Akero Therapeutics dividend payment date?
Akero Therapeutics (AKRO) stock does not pay dividends to its shareholders.
What is the beta indicator for Akero Therapeutics?
Akero Therapeutics (AKRO) has a beta rating of -0.28. This means that it has an inverse relation to market volatility.